News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UCB, Inc. (UCBJF.PK)'s RA Drug Does Not Overly Impress in Phase II


9/28/2012 8:11:00 AM

For most companies the prospect of temporarily mothballing your fourth most-valuable product in development would spell share price disaster, but the decision to call a halt on independent development for the phase II MAb olokizumab barely registered for UCB (UCBJY.PK). Shares in the group were flat at €43.47 in afternoon trading. What appears to be making UCB bulletproof for the time being is that the Brussels-based company, unlike many of its European peers, is set to emerge from its patent expiry cliff by the end of the year; add to this what many analysts see as strong growth prospects for a trio of its newer products and UCB can afford to have this developmental hiccup.


comments powered by Disqus
UCB, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES